At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 277 enrolled
Drug / intervention
Methotrexate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Methotrexate Discontinuation on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial
In Brief
A Phase 4 clinical trial evaluating Methotrexate and Seasonal Influenza vaccine for Arthritis, Rheumatoid. Completed, enrolled 277 participants across 1 site.
Detailed Summary
To investigate whether a short term discontinuation of methotrexate (MTX) will improve the vaccination efficacy to seasonal influenza vaccination without deteriorating RA disease activity in a randomized clinical trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedApr 2016
Primary CompletionAug 2016
TodayJul 2026
First PostedApr 22, 2016
Enrollment StartSep 1, 2015
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.2 years ago
Interventions
Methotrexatedrug
Methotrexate will be continued
Seasonal Influenza vaccinebiological
all subjects will be vaccinated with a seasonal influenza vaccine